Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study).
To evaluate the impact of late reperfusion of an infarct-related coronary artery on left ventricular (LV) function in the month after myocardial infarction, findings from 368 patients in the Intravenous Streptokinase in Myocardial Infarction study are presented. All patients had a late peaking in the creatine kinase-MB serum time-activity curve, suggesting absence of early reperfusion. Contrast angiography was performed 1 month after the acute event. The infarct-related coronary artery was patent in 74 of 116 (64%) streptokinase-treated patients and 141 of 252 (56%) patients treated with anticoagulant therapy (placebo group). In all baseline variables, including the actually developed enzymatic and electrocardiographic infarct sizes, there were no differences between the patent- or occluded-artery groups. A patent infarct artery 1 month after infarction was associated with significantly better LV function regardless of the vessel involved and whether or not patients had been treated with streptokinase. Ejection fraction in patients with patent versus occluded artery was 56 +/- 13 versus 50 +/- 14 (p less than 0.0005). Most benefit was noted in patients in whom the proximal left anterior descending coronary artery was affected: ejection fraction was 52 +/- 14 versus 36 +/- 12% (p less than 0.0005). Our data confirm that restoration of adequate flow through an infarct-related coronary artery beyond the time window for actual salvage of ischemic myocardium has a definite beneficial effect on LV function.
Schröder
R
R
ISAM Coordinating Center, Berlin, West Germany.
Neuhaus
K L
KL
Linderer
T
T
Brüggemann
T
T
Tebbe
U
U
Wegscheider
K
K
D000368:Aged; D017023:Coronary Angiography; D003402:Creatine Kinase / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy; D015425:Myocardial Reperfusion; D012189:Retrospective Studies; D013300:Streptokinase / Q000627:therapeutic use; D013318:Stroke Volume; D013997:Time Factors; D014654:Vascular Patency
D003402:Creatine Kinase; D013300:Streptokinase